The deal values Relievant Medsystems at $850 million, and additional payments are expected over the next three years, according to a Sept. 19 news release.
Intracept is a minimally invasive, implant-free outpatient procedure aimed to address lower back pain. Its efficacy is backed by clinical trials.
The acquisition is explected to close in the first half of 2024.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.